Characterisation of ilomastat for prolonged ocular drug release

AAPS PharmSciTech

Volumn 13, Issue 4, 2012, Pages 1063-1072

  Parkinson, Gary ^a   Gaisford, Simon ^a   Ru, Qian ^a,b   Lockwood, Alastair ^a,b   Khalili, Ashkan ^a,b   Sheridan, Rose ^c   Khaw, Peng T ^b   Brocchini, Steve ^a,b   Fadda, Hala M ^a,b,d  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d BUTLER UNIVERSITY   (United States)

Author keywords

biorelevant media; dissolution; enantiotrope; ocular drug delivery; solid solid transition

Indexed keywords

ILOMASTAT;

ARTICLE; CALORIMETRY; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CONFORMATION; DRUG FORMULATION; DRUG RELEASE; IN VITRO STUDY; PRIORITY JOURNAL; X RAY POWDER DIFFRACTION;

ABSORBABLE IMPLANTS; ADMINISTRATION, OPHTHALMIC; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DELAYED-ACTION PREPARATIONS; INDOLES; POWDERS; TABLETS; X-RAY DIFFRACTION;

EID: 84871654197     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-012-9832-1     Document Type: Article

References (30)

1. Pudipeddi M, Serajuddin ATM. Trends in solubility of polymorphs. J Pharm Sci. 2005;94(5):929-39.
2. Datta S, Grant DJW. Crystal structures of drugs: advances in determination, prediction and engineering. Nat Rev Drug Discov. 2004;3(1):42-57.
3. Giron D, Goldbronn C, Mutz M, Pfeffer S, Piechon P, Schwab P. Solid state characterizations of pharmaceutical hydrates. J Therm Anal Calorim. 2002;68(2):453-65.
4. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363(9422):1711-20. Epub 2004/05/26.
5. Reynolds AC, Skuta GL, Monlux R, Johnson J. Management of blebitis by members of the American Glaucoma Society: a survey. J Glaucoma. 2001;10(4):340-7.
6. Parrish R, Minckler D. "Late endophthalmitis" - filtering surgery time bomb? Ophthalmology. 1996;103(8):1167-8.
7. Georgoulas S, Dahlmann-Noor A, Brocchini S, Khaw PT. Modulation of wound healing during and after glaucoma surgery. Glaucoma: an open window in to neurodegeneration and neuroprotection. Prog Brain Res. 2008;173:237-54.
8. Wong TTL, Mead AL, Khaw PT. Matrix metalloproteinase inhibition modulates postoperative scarring after experimental glaucoma filtration surgery. Investig Ophthalmol Vis Sci. 2003;44(3):1097-103.
9. Wong TT, Mead AL, Khaw PT. Prolonged antiscarring effects of ilomastat and MMC after experimental glaucoma filtration surgery. Investig Ophthalmol Vis Sci. 2005;46(6):2018-22. Epub 2005/05/26.
10. Georgoulas S, Ru Q, Brocchini S, Khaw P. A novel single application prolonged release MMP inhibitor is superior to mitomycin in preventing scarring after experimental glaucoma surgery. Investig Ophthalmol Vis Sci. 2008;49:A4538.
11. Sheridan CM, Occleston NL, Hiscott P, Kon CH, Khaw PT, Grierson I. Matrix metalloproteinases: a role in the contraction of vitreo-retinal scar tissue. Am J Pathol. 2001;159(4):1555-66. Epub 2001/10/05.
12. Townley WA, Cambrey AD, Khaw PT, Grobbelaar AO. The role of an MMP inhibitor in the regulation of mechanical tension by Dupuytren's disease fibroblasts. J Hand Surg Eur Vol. 2009;34(6):783-7. Epub 2009/09/30.
13. Brochhausen C, Schmitt VH, Rajab TK, Planck CN, Kramer B, Wallwiener M, et al. Intraperitoneal adhesions - an ongoing challenge between biomedical engineering and the life sciences. J Biomed Mater Res A. 2011;98(1):143-56. Epub 2011/05/07.
14. McLaren JW. Measurement of aqueous humor flow. Exp Eye Res. 2009;88(4):641-7.
15. Altomare A, Cascarano G, Giacovazzo C, Guagliardi A. Completion and refinement of crystal-structures with Sir92. J Appl Crystallogr. 1993;26:343-50.
16. Sheldrick GM, Schneider TR. SHELXL: high-resolution refinement. Macromol Crystallogr Part B. 1997;277:319-43.
17. Kawasaki S, Mizoue S, Yamaguchi M, Shiraishi A, Zheng X, Hayashi Y, et al. Evaluation of filtering bleb function by thermography. Br J Ophthalmol. 2009;93(10):1331-6.
18. Mackin L, Zanon R, Park JM, Foster K, Opalenik H, Demonte M. Quantification of low levels (<10%) of amorphous content in micronised active batches using dynamic vapour sorption and isothermal microcalorimetry. Int J Pharm. 2002;231(2):227-36.
19. Gaisford S, Dennison M, Tawfik M, Jones MD. Following mechanical activation of salbutamol sulphate during ball-milling with isothermal calorimetry. Int J Pharm. 2010;393(1-2):74-8.
20. Vippagunta SR, Brittain HG, Grant DJW. Crystalline solids. Adv Drug Deliv Rev. 2001;48(1):3-26.
21. Newman AW, Reutzel-Edens SM, Zografi G. Characterization of the "Hygroscopic" properties of active pharmaceutical ingredients. J Pharm Sci. 2008;97(3):1047-59.
22. Barbas R, Marti F, Prohens R, Puigjaner C. Polymorphism of norfloxacin: evidence of the enantiotropic relationship between polymorphs A and B. Cryst Growth Des. 2006;6(6):1463-7.
23. Fadda HM, Sousa T, Carlsson AS, Abrahamsson B, Williams JC, Kumar D, et al. Drug solubility in luminal fluids from different regions of the small and large intestine of humans. Mol Pharm. 2010;7(5):1527-32.
24. Fadda HM, Basit AW. Dissolution of pH responsive formulations in media resembling intestinal fluids: bicarbonate versus phosphate buffers. J Drug Deliv Sci Tech. 2005;15(4):273-9.
25. Mooney KG, Mintun MA, Himmelstein KJ, Stella VJ. Dissolution kinetics of carboxylic acids II: effect of buffers. J Pharm Sci. 1981;70(1):22-32. Epub 1981/01/01.
26. Daniels JT, Cambrey AD, Occleston NL, Garrett Q, Tarnuzzer RW, Schultz GS, et al. Matrix metalloproteinase inhibition modulates fibroblast-mediated matrix contraction and collagen production in vitro. Investig Ophthalmol Vis Sci. 2003;44(3):1104-10.
27. Fisher JF, Mobashery S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev. 2006;25(1):115-36.
28. Aguiar AJ, Krc J, Kinkel AW, Samyn JC. Effect of polymorphism on absorption of chloramphenicol from chloramphenicol palmitate. J Pharm Sci. 1967;56(7):847-53.
29. Aguiar AJ, Zelmer JE. Dissolution behavior of polymorphs of chloramphenicol palmitate and mefenamic acid. J Pharm Sci. 1969;58(8):983-7.
30. Khalafallah N, Khalil SA, Moustafa MA. Bioavailability determination of 2 crystal forms of sulfameter in humans from urinary-excretion data. J Pharm Sci. 1974;63(6):861-4.